hormone, suggesting that 1,25(OH)2D3 negatively feedback controls its levels by inducing FGF23. To establish the tissue of origin and the molecular mechanism by which 1,25(OH) 2D3 increases circulating FGF23, we administered 1,25(OH)2D3 to C57BL/6 mice. Within 24 h, these mice displayed a dramatic elevation in serum immunoreactive FGF23, and the expression of FGF23 mRNA in bone was significantly upregulated by 1,25(OH) 2D3, but there was no effect in several other tissues. Furthermore, we treated rat UMR-106 osteoblast-like cells with 1,25(OH) 2 D 3 , and real-time PCR analysis revealed a dose-and time-dependent stimulation of FGF23 mRNA concentrations. The maximum increase in FGF23 mRNA was 1,024-fold at 10 Ϫ7 M 1,25(OH)2D3 after 24-h treatment, but statistically significant differences were observed as early as 4 h after 1,25(OH) 2D3 treatment. In addition, using cotreatment with actinomycin D or cycloheximide, we observed that 1,25(OH) 2D3 regulation of FGF23 gene expression occurs at the transcriptional level, likely via the nuclear vitamin D receptor, and is dependent on synthesis of an intermediary transfactor. These results indicate that bone is a major site of FGF23 expression and source of circulating FGF23 after 1,25(OH) 2D3 administration or physiological upregulation. Our data also establish FGF23 induction by 1,25(OH) 2D3 in osteoblasts as a feedback loop between these two hormones that completes a kidneyintestine-bone axis that mediates phosphate homeostasis. fibroblast growth factor 23; gene regulation INORGANIC PHOSPHORUS (P i ) is required for skeletal mineralization, energy transfer, cellular signaling, and regulation of protein function. The homeostasis of serum P i levels is effected through a complex interplay between intestinal absorption, exchange with intracellular and bone storage pools, and renal tubular reabsorption. These processes are primarily regulated by parathyroid hormone (PTH) and 1␣,25-dihydroxyvitamin D [1,25(OH) 2 D 3 ] (5, 7, 19). Recently, a growing body of evidence suggests that other factors of bone origin participate in maintaining P i homeostasis, such as fibroblast growth factor (FGF)23, matrix extracellular phosphoglycoprotein, and frizzled-related protein 4. These factors, known collectively as the phosphatonins, have been shown to be associated with hypophosphatemic diseases, including autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), and X-linked hypophosphatemic rickets (XLH) (1-4, 6, 8, 9, 12, 16 -18, 20 -22, 26 -29, 31-33).
INORGANIC PHOSPHORUS (P i ) is required for skeletal mineralization, energy transfer, cellular signaling, and regulation of protein function. The homeostasis of serum P i levels is effected through a complex interplay between intestinal absorption, exchange with intracellular and bone storage pools, and renal tubular reabsorption. These processes are primarily regulated by parathyroid hormone (PTH) and 1␣,25-dihydroxyvitamin D [1, 25(OH) 2 D 3 ] (5, 7, 19) . Recently, a growing body of evidence suggests that other factors of bone origin participate in maintaining P i homeostasis, such as fibroblast growth factor (FGF)23, matrix extracellular phosphoglycoprotein, and frizzled-related protein 4. These factors, known collectively as the phosphatonins, have been shown to be associated with hypophosphatemic diseases, including autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), and X-linked hypophosphatemic rickets (XLH) (1-4, 6, 8, 9, 12, 16 -18, 20 -22, 26 -29, 31-33) .
Among these factors, FGF23 is the only protein to date that has been linked to all three disorders. Missense mutations in FGF23, which likely prevent its cleavage and inactivation, are the cause of ADHR (1) . Administration of an ADHR mutant form of FGF23 to mice inhibited sodium-phosphate cotransport activities in both the kidney (NaP i -2a) and small intestine (NaP i -2b), and suppressed 1,25(OH) 2 D 3 (22) . Ectopic overproduction of FGF23 overwhelms its processing and degradation, leading to TIO (26) . Administration of recombinant FGF23 in normal and parathyroidectomized animals induced a decrease in serum phosphate levels, phosphaturia accompanied by a reduction in renal mRNA and protein levels for NaP i -2a, a decrease in renal mRNA for 25-hydroxyvitamin D-1␣-hydroxylase, and an increase in 25-hydroxyvitamin D-24-hydroxylase, the cytochrome P-450 enzymes that generate and inactivate 1,25(OH) 2 D 3 hormone, respectively (24, 26) . Mice implanted with FGF23-expressing Chinese hamster ovary (CHO) cells showed more severe hypophosphatemia, osteomalacia, and decreased 1,25(OH) 2 D 3 levels (26). Conversely, FGF23-null mice exhibited increased circulating 1,25(OH) 2 D 3 despite hyperphosphatemia, hypercalcemia, and low PTH levels (25) . Elevated circulating FGF23 levels have also been found in most, but not all, patients with XLH (12, 33) .
FGF23 mRNA is expressed in a variety of human and mouse tissues, including the following: bone (calvaria, mandible, long bone, femoral heads), brain, thymus, small intestine, heart, lung, liver, kidney, thyroid/parathyroid, lymph node, skeletal muscle, spleen, skin, stomach, and testis (1, 14, 26, 32) . Among these tissues, FGF23 mRNA expression is found to be highest in bone in both the human and mouse. Liu et al. (14) reported that Hyp mice express markedly increased FGF23 levels in the calvaria, mandible, and long bone compared with normal mice. The increase of FGF23 in Hyp mice was limited to bone with no observable increases of FGF23 in the bone marrow, kidney, lung, or liver (14) .
Regulation of FGF23 production is still unclear. Recent studies have revealed that circulating FGF23 is regulated by serum P i controlled by dietary P i in five-sixth nephrectomized rats (23 (11, 23) .
In this study, we examined the effect of 1,25(OH) 2 D 3 on FGF23 mRNA expression levels in different mouse tissues to identify the major source of elevated circulating FGF23. We also investigated the molecular mechanism whereby 1,25(OH) 2 
MATERIALS AND METHODS
Experimental animals. Four-to five-week-old male C57BL/6 mice in groups of three to four were subcutaneously injected once a day for 2 days with either vehicle (1:4, ethanol-propylene glycol) or 6 g/kg body wt 1,25(OH) 2D3 (Sigma; St. Louis, MO) (30) . Animals were supplied with food and water ad libitum. Mice were killed 24 h after the second 1,25(OH) 2D3 injection by CO2 narcosis followed by decapitation. Trunk blood was collected, allowed to clot, centrifuged to obtain serum, and stored at Ϫ70°C. Tissues (calvaria, tibia, jejunum, liver, spleen, kidney, and brain) were removed, flash frozen in liquid nitrogen, and stored at Ϫ70°C. All methods used in this study were approved by the Institutional Animal Care and Use Committee of the University of Arizona.
Chemicals and reagents. Sodium pyruvate (100 mM), 100ϫ antibiotic-antimycotic, and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA). Dulbecco's modified Eagle's high-glucose medium and FBS were from Irvine Scientific (Santa Ana, CA). FGF23 and 18S Taqman primer/probe sets were purchased from Applied Biosystems (Foster City, CA). iScript cDNA Synthesis Kit and iQ Supermix were from Bio-Rad (Hercules, CA). The DNA-free kit was purchased from Ambion (Austin, TX). All other reagents, unless otherwise indicated, were purchased from Sigma.
Real-time PCR. Ten micrograms of total RNA were treated with DNase I according to the DNA-free kit protocol (Ambion). The resulting RNA was evaluated by agarose gel electrophoresis, and concentrations were adjusted according to densitometric analysis of the 18S rRNA band. DNase I-treated RNA (250 ng) was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's protocol. Subsequently, 20-l PCRs were set up in 96-well plates containing 10 l iQ Supermix, 1 l TaqMan primer/probe set, 2 l cDNA synthesis reaction (out of a 20-l total volume), and 7 l molecular grade water. Reactions were run and analyzed on a Bio-Rad iCycler iQ Real-Time PCR detection system. Cycling parameters were determined, and resulting data were analyzed according to ABI protocols. Briefly, data were analyzed using the comparative cycle threshold (C T) method as a means of relative quantitation, normalized to an endogenous reference (18S rRNA) and relative to a calibrator [normalized C T value obtained from ethanol (EtOH)-treated UMR-106 cells or mice], and expressed as 2{Ϫ⌬⌬C T} according to Applied Biosystems User Bulletin no. 2: Rev B Relative Quantitation Of Gene Expression. Applied Biosystems does not supply the sequence of the custom-designed FGF23 primer/probe sets; therefore, we independently designed and obtained PCR primers encompassing mouse and rat FGF23 gene coding regions. These independent primers yielded essentially equivalent results for FGF23 mRNA induction by 1,25(OH) 2D3 in the mouse in vivo (see Fig. 2 ) and UMR-106 cells in vitro (see Fig. 4 ) (data not shown). This result eliminates the unlikely possibility of an error in the Applied Biosystems primer/probe construction causing the amplification of a gene unrelated to FGF23.
FGF23 ELISA kit. Serum FGF23 was determined using a FGF-23 ELISA kit (Kainos Laboratories; Tokyo, Japan).
Cell culture. Rat osteogenic sarcoma cells (UMR-106) were obtained from the American Type Culture Collection. UMR-106 cells were cultured in Dulbecco's modified Eagle's high-glucose media containing 10% FBS, 1 mM sodium pyruvate, and 1ϫ antibioticantimycotic. Cell cultures were maintained at 37°C with 5% CO 2. For analysis of endogenous FGF23 gene expression, cells were seeded on six-well plates at 0.3 ϫ 10 6 cells/well and treated with 10 Ϫ7 M 1,25(OH)2D3 or EtOH 48 h postseeding. Where indicated, 1 g/ml actinomycin D (Calbiochem; San Diego, CA) or 10 M cycloheximide (Sigma) was added 30 min before 1,25(OH) 2D3 or EtOH treatment and continued throughout the treatment period. In each experiment, the results from three wells for six-well plates were averaged and considered as n ϭ 1. There was no significant variance among the individual wells in each averaged group.
Statistical analysis. Statistical significance was determined by the Student's t-test or ANOVA followed by Fisher's protected leastsignificant difference test using StatView software package version 4.53 (SAS Institute; Cary, NC). All data are expressed as means Ϯ SE.
RESULTS

1,25(OH) 2 D 3 increases serum FGF23 in mice.
We first reexamined and confirmed recent reports showing that 1,25(OH) 2 D 3 increases circulating FGF23 in vivo (23, 24) . As shown in Fig.  1 , a dramatic elevation of serum FGF23 levels was observed FGF23 expression is increased in bone of 1,25(OH) 2 D 3 -injected mice. We next investigated whether FGF23 mRNA expression is regulated by 1,25(OH) 2 D 3 in vivo. We examined the expression of FGF23 mRNA in tissues of vehicle-injected mice using real-time PCR. Our findings are in agreement with prior reports (14) showing that FGF23 expression is highest in bone followed by the spleen, brain, jejunum, and liver, with nearly undetectable levels in the kidney ( Fig. 2A; n ϭ 3) . Next, we compared FGF23 mRNA expression in tissues of mice injected with 1,25(OH) 2 D 3 or vehicle. 1,25(OH) 2 D 3 markedly increased FGF23 mRNA levels in the calvaria (57 Ϯ 1.7-fold) and tibia (8 Ϯ 0.7-fold) ( Fig. 2B ; n ϭ 4, P Ͻ 0.0001). However, no significant increases in FGF23 mRNA were observed in several nonbone tissues derived from 1,25(OH) 2 D 3 -injected mice (Fig. 2C) Fig. 2 and other reports suggest that FGF23 is expressed mainly in bone. FGF23 transcripts have also been found in primary human osteoblast-like bone cells (15) and immortalized osteoblast cell lines derived from wild type (TMOb-Nl) and Hyp (TMOb-Hyp) mice (14) . We detected FGF23 expression by real-time PCR in the rat osteogenic sarcoma cell line UMR-106.
To determine whether 1,25(OH) 2 D 3 had a similar effect on FGF23 mRNA expression in bone and in cultured osteoblasts, and to evaluate the dose dependency of that effect, UMR-106 cells were incubated for 24 h with the hormone at doses ranging from 10 Ϫ9 -10 Ϫ7 M. As shown in Fig. 3 , we found Fig. 5 ; n ϭ 5, P Ͻ 0.0001). Interestingly, as shown in Fig. 6 , pretreatment with cycloheximide also prevented the 1,25(OH) 2 D 3 effect on FGF23 mRNA expression in osteoblast-like cells (n ϭ 4, P Ͻ 0.0001). Thus the induction of FGF23 by 1,25(OH) 2 D 3 in rat osteoblast-like cells is a transcriptional effect (Fig. 5) , likely mediated by the nuclear VDR (13), but because ongoing protein synthesis is required for this action (Fig. 6 ), a rapidly turned over intermediary transfactor appears to participate in the mechanism.
DISCUSSION
It has been reported recently that a single injection of 1,25(OH) 2 D 3 increased serum FGF23 in normal mice (24) . Moreover, Saito et al. (23) showed that the 1,25(OH) 2 D 3 effect on circulating FGF23 was dose dependent and independent of serum P i in normal and thyroparathyroidectomized rats. In the present study, we investigated a contributing source of circulating FGF23 in 1,25(OH) 2 D 3 injected mice and the molecular mechanisms by which 1,25(OH) 2 D 3 regulates FGF23 mRNA expression in rat osteoblast-like cells.
We first showed that the levels of serum FGF23 in mice after 1,25(OH) 2 D 3 injection were significantly elevated compared with FGF23 concentrations after EtOH administration (Fig. 1) . Next, we confirmed, by real-time PCR, that expression of FGF23 mRNA in bone is high relative to other mouse tissues previously reported to express FGF23 (Fig. 2A) . Additionally, we examined mRNA levels for FGF23 in several mouse tissues, including bone (calvaria and tibia), jejunum, kidney, liver, spleen, and brain, after a subcutaneous injection of 1,25(OH) 2 D 3 . We observed that 1,25(OH) 2 D 3 markedly increased FGF23 mRNA expression in bone (calvaria and tibia; Fig. 2B ). The increase in FGF23 mRNA in 1,25(OH) 2 D 3 -injected mice was limited to the skeleton because levels of FGF23 mRNA expression in other tissues of 1,25(OH) 2 D 3 -treated mice were similar to levels of FGF23 found in vehicletreated mice. Observations such as high FGF23 expression in bone, large total mass of the skeleton, and a bone-restricted increase in FGF23 mRNA levels after 1,25(OH) 2 Recent studies revealed that the levels of serum FGF23 in VDR-null mice (VDR knockout mice) were significantly lower than those in wild-type mice, and VDR knockout mice did not respond to 1,25(OH) 2 D 3 administration (11, 23) . However, the molecular mechanism by which 1,25(OH) 2 (Fig. 3) . Moreover, Ito et al. (11) (Fig. 4) , consistent with transcriptional regulation of FGF23 expression by the hormone. Consequently, to confirm this hypothesis, we cotreated UMR-106 cells with a DNA transcription inhibitor, actinomycin D, and 1,25(OH) 2 D 3 . As expected, actinomycin D abolished the effect of 1,25(OH) 2 D 3 on FGF23 mRNA (Fig. 5) . Surprisingly, (Fig. 6) . Thus it is likely that a labile protein is required for 1,25(OH) 2 D 3 induction of FGF23 in bone cells. This hypothesized protein may be a cofactor in the 1,25(OH) 2 D 3 -VDR/ retinol X receptor (RXR) nuclear receptor complex that activates transcription (13) at the level of the FGF23 promoter. Alternatively, the transcriptional action of 1,25(OH) 2 D 3 -VDR/ RXR on FGF23 could be secondarily mediated by the activation of a primary transactivator, which, in turn, stimulates the FGF23 promoter. This second notion is consistent with the apparent lack of VDREs in the mouse FGF23 proximal promoter (11).
In conclusion, there exists a feedback loop among P i , 1,25(OH) 2 D 3 , and FGF23 as part of a kidney-intestine-bone hormonal axis that is hypothesized to play a key role in phosphate homeostasis. This axis is depicted schematically in Fig. 7 . In this model, 1,25(OH) 2 D 3 is produced in the kidney by 1␣-OHase, an enzyme that is induced under low circulating phosphate situations to generate excess 1,25(OH) 2 D 3 to enhance phosphate absorption from the intestine, reabsorption from the kidney, and resorption from bone, thereby correcting hypophosphatemia (10) . Calcium absorption from the small intestine is also enhanced by 1,25(OH) 2 D 3 , acting via VDR and the induction of calcium transport machinery (10) . The resulting increased calcium and phosphate in the blood exceed their ion products and promote bone mineralization (Fig. 7) . Importantly, to ensure phosphate homeostasis and prevent hyperphosphatemic spikes that would precipitate ectopic calcification, enhanced 1,25(OH) 2 D 3 also induces FGF23 synthesis and release from bone, specifically, the osteoblast endocrine cell (Fig. 7) . Increased FGF23 then, as illustrated in Fig. 7 , would close the endocrine loop, both by eliciting phosphaturia via inhibition of NaP i -2a in the kidney and by repressing renal 1␣-OHase, resulting in the correct adjustment in circulating PO 4 3Ϫ and 1,25(OH) 2 D 3 . The present data (Figs. 1-4 ) support the conclusion that 1,25(OH) 2 D 3 -induced FGF23 from bone constitutes the final link in a renal-gastrointestinal-skeletal axis that controls serum phosphate and active vitamin D levels.
Finally, as depicted in Fig. 7 , low circulating calcium conditions stimulate renal 1␣-OHase through the alternative pathway of increased PTH secretion (10). 1,25(OH) 2 D 3 in turn activates both calcium and phosphate absorption from the intestine, with the former correcting hypocalcemia but the latter possibly eliciting hyperphosphatemia. Initially, this hyperphosphatemia could be compensated for by PTH-triggered phosphaturia, although this will be short lived because the corrected serum calcium will suppress PTH. We propose that in the long term, 1,25(OH) 2 D 3 induction of FGF23 provides protection against hyperphosphatemia associated with restoring serum calcium levels, which may explain why there is a need for two hypophosphatemic hormones, PTH and FGF23. Clearly the role of PTH is more significant in the calciumvitamin D axis, whereas FGF23 mediates the phosphate-vitamin D axis.
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